Abnormal expression of the mitotic checkpoint protein BubR1 contributes to the anti-microtubule drug resistance of esophageal squamous cell carcinoma cells

Hu,Min; Liu,Qingsong; Song,Peipei; Zhan,Xiaoqin; Luo,Min; Liu,Chen; Yang,Dandan; Cai,Yan; Zhang,Fan; Jiang,Fengbing; Zhang,Yan; Tang,Min; Zuo,Guowei; Zhou,Lan; Luo,Jinyong; Shi,Qiong; Weng,Yaguang

doi:10.3892/or.2012.2117

Abnormal expression of the mitotic checkpoint protein BubR1 contributes to the anti-microtubule drug resistance of esophageal squamous cell carcinoma cells

Authors:
- Min Hu
- Qingsong Liu
- Peipei Song
- Xiaoqin Zhan
- Min Luo
- Chen Liu
- Dandan Yang
- Yan Cai
- Fan Zhang
- Fengbing Jiang
- Yan Zhang
- Min Tang
- Guowei Zuo
- Lan Zhou
- Jinyong Luo
- Qiong Shi
- Yaguang Weng
View Affiliations

Affiliations: Key Laboratory of Diagnostic Medicine designated by The Chinese Ministry of Education and School of Diagnostic Medicine, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Laboratory Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China
Published online on: October 31, 2012 https://doi.org/10.3892/or.2012.2117
Pages: 185-192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal cancer is a common malignancy with a high mortality rate. The lack of effective chemotherapy and a means to overcome drug resistance leads to the predictable failure of esophageal cancer treatment. Mitotic checkpoint proteins play a critical role in regulating the cell cycle and proliferation. Abnormal expression of the mitotic checkpoint protein BubR1 has been reported in several types of cancers. In this study, we investigated the role of BubR1 in conferring resistance of esophageal cancer cells to anti-microtubule drugs. Using quantitative real-time PCR analysis on 50 samples of paired esophageal squamous cell cancer (ESC) tissues and adjacent non-cancerous tissues, we found that 72% (36 of 50) of the analyzed ESC samples exhibited high expression levels of BubR1, which was also confirmed in ESC cell lines. ESC cells with high levels of BubR1 were less sensitive to the anti-microtubule drugs paclitaxel and nocodazole. Recombinant adenovirus-mediated enforced expression of BubR1 in relatively sensitive ESC cell lines resulted in increased resistance to paclitaxel. Conversely, RNAi-mediated knockdown of BubR1 restored ESC cell sensitivity to paclitaxel. Cell cycle analysis indicated that the sub-G1 population increased in the ESC cells with reduced BubR1 levels. Taken together, our results suggest that upregulation of BubR1 expression may be associated with ESC resistance to paclitaxel treatment. Thus, BubR1 may serve as a potential chemosensitizing target to overcome chemoresistance.

View Figures

View References

1	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
2	Stathopoulos GP and Tsiaras N: Epidemiology and pathogenesis of esophageal cancer: management and its controversial results (Review). Oncol Rep. 10:449–454. 2003.PubMed/NCBI
3	Musacchio A and Salmon ED: The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 8:379–393. 2007. View Article : Google Scholar : PubMed/NCBI
4	Bolanos-Garcia VM and Blundell TL: BUB1 and BUBR1: multifaceted kinases of the cell cycle. Trends Biochem Sci. 36:141–150. 2011. View Article : Google Scholar : PubMed/NCBI
5	Elowe S, Dulla K, Uldschmid A, Li X, Dou Z and Nigg EA: Uncoupling of the spindle-checkpoint and chromosome-congression functions of BubR1. J Cell Sci. 123:84–94. 2010. View Article : Google Scholar : PubMed/NCBI
6	Sotillo R, Hernando E, Díaz-Rodríguez E, Teruya-Feldstein J, Cordón-Cardo C, Lowe SW and Benezra R: Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell. 11:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ricke RM, Jeganathan KB and van Deursen JM: Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation. J Cell Biol. 193:1049–1064. 2011. View Article : Google Scholar : PubMed/NCBI
8	Yuan B, Xu Y, Woo JH, et al: Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 12:405–410. 2006. View Article : Google Scholar : PubMed/NCBI
9	Yamamoto Y, Matsuyama H, Chochi Y, et al: Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogen. 174:42–47. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ando K, Kakeji Y, Kitao H, et al: High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci. 101:639–645. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lee YK, Choi E, Kim MA, Park PG, Park NH and Lee H: BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer. 101:504–510. 2009. View Article : Google Scholar : PubMed/NCBI
12	Pinto M, Vieira J, Ribeiro FR, et al: Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol. 30:389–395. 2008.PubMed/NCBI
13	Tanaka K, Mohri Y, Ohi M, et al: Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 20:639–646. 2008. View Article : Google Scholar
14	Hanks S, Coleman K, Reid S, et al: Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet. 36:1159–1161. 2004. View Article : Google Scholar : PubMed/NCBI
15	Dai W, Wang Q, Liu T, et al: Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res. 64:440–445. 2004. View Article : Google Scholar : PubMed/NCBI
16	Baker DJ, Perez-Terzic C, Jin F, et al: Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol. 10:825–836. 2008. View Article : Google Scholar : PubMed/NCBI
17	Baker DJ, Jeganathan KB, Cameron JD, et al: BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet. 36:744–749. 2004. View Article : Google Scholar : PubMed/NCBI
18	Kim M, Murphy K, Liu F, Parker SE, Dowling ML, Baff W and Kao GD: Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression. Mol Cell Biol. 25:9232–9248. 2005. View Article : Google Scholar : PubMed/NCBI
19	Sudo T, Nitta M, Saya H and Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 64:2502–2508. 2004. View Article : Google Scholar : PubMed/NCBI
20	Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G and Kao GD: Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther. 3:661–669. 2004.PubMed/NCBI
21	Fu Y, Ye D, Chen H, Lu W, Ye F and Xie X: Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol. 105:66–73. 2007. View Article : Google Scholar : PubMed/NCBI
22	Yamada HY and Gorbsky GJ: Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons. Mol Cancer Ther. 5:29–38. 2006. View Article : Google Scholar : PubMed/NCBI
23	Shin HJ, Baek KH, Jeon AH, et al: Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell. 4:483–497. 2003. View Article : Google Scholar : PubMed/NCBI
24	Luo J, Deng Z-L, Luo X, et al: A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
25	Hannisdal K, Burum-Auensen E, Schjolberg A, De Angelis PM and Clausen OP: Correlation between reduced expression of the spindle checkpoint protein BubR1 and bad prognosis in tonsillar carcinomas. Head Neck. 32:1354–1362. 2010. View Article : Google Scholar : PubMed/NCBI
26	Rao CV, Yang YM, Swamy MV, et al: Colonic tumorigenesis in BubR1^+/−Apc^Min/⁺ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl Acad Sci USA. 102:4365–4370. 2005.PubMed/NCBI
27	Seike M, Gemma A, Hosoya Y, et al: The promoter region of the human BUBR1 gene and its expression analysis in lung cancer. Lung Cancer. 38:229–234. 2002. View Article : Google Scholar : PubMed/NCBI
28	Menssen A, Epanchintsev A, Lodygin D, et al: c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle. 6:339–352. 2007. View Article : Google Scholar : PubMed/NCBI
29	Park HY, Jeon YK, Shin HJ, et al: Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells. Exp Mol Med. 39:195–204. 2007. View Article : Google Scholar : PubMed/NCBI
30	Wu YC, Yen WY and Yih LH: Requirement of a functional spindle checkpoint for arsenite-induced apoptosis. J Cell Biochem. 105:678–687. 2008. View Article : Google Scholar : PubMed/NCBI